<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00143689</url>
  </required_header>
  <id_info>
    <org_study_id>H02-50066</org_study_id>
    <secondary_id>CTN 177</secondary_id>
    <nct_id>NCT00143689</nct_id>
  </id_info>
  <brief_title>NRTI-Sparing Pilot Study</brief_title>
  <official_title>A Pilot Study of a Nucleoside Analogue Reverse Transcriptase Inhibitor Sparing Regimen in Antiretroviral-Na√Øve, HIV-infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>CIHR Canadian HIV Trials Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of British Columbia</source>
  <brief_summary>
    <textblock>
      This study will compare a nucleoside reverse transcriptase inhibitor-sparing (NRTI-sparing)
      regimen (Kaletra + nevirapine) to two nucleoside reverse transcriptase inhibitor-based
      regimens (Combivir + nevirapine and Combivir + Kaletra).

      Participants will be randomly assigned to receive one of the following drug combinations:

        -  lopinavir/ritonavir (Kaletra) and nevirapine (Viramune) twice a day;

        -  Combivir (Zidovudine (AZT) plus lamivudine (3TC)) and nevirapine twice a day;

        -  Combivir and lopinavir/ritonavir twice a day.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in mitochondrial DNA/Nuclear DNA (mtDNA/nDNA) ratio at 48 weeks, as a marker of mitochondrial toxicity.</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in mitochondrial DNA/Nuclear DNA (mtDNA/nDNA) ratio at 96 weeks</measure>
    <time_frame>96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of patients with viral load below 50 and below 400 copies/mL</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral load changes from baseline</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates and extent of immune reconstitution (CD4 count increase)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates and severity of dyslipidemia and insuline resistance/diabetes</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>HIV</condition>
  <condition>Mitochondrial Toxicity</condition>
  <arm_group>
    <arm_group_label>Lopinavir/ritonavir, Zidovudine, Lamivudine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomly assigned to receive one of the following drug combinations:
lopinavir/ritonavir (Kaletra) and nevirapine (Viramune) twice a day;
Combivir (Zidovudine (AZT) plus lamivudine (3TC)) and nevirapine twice a day;
Combivir and lopinavir/ritonavir twice a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine</intervention_name>
    <description>See Detailed Description.</description>
    <arm_group_label>Lopinavir/ritonavir, Zidovudine, Lamivudine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be HIV-positive

          -  Be at least18 years of age

          -  Have viral load above 5 000 copies/ml

          -  Be likely to comply with the study protocol

          -  Agree not to take, for the duration of the study, any drug that is contraindicated
             with the study drugs

          -  Agree not to take any medication, including over-the-counter medicine, alcohol, or
             street drugs without the knowledge and permission of the principal investigator

        Exclusion Criteria:

          -  Have ever received antiretroviral therapy

          -  Pregnancy or breastfeeding

          -  Have abnormal laboratory tests (see investigator)

          -  Have received an investigational drug within 30 days of study drugs administration

          -  Be receiving systemic chemotherapy

          -  Have an acute illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julio Montaner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia/Providence Health Care</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Health Services</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maple Leaf Clinic</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Medicale L'Actuel</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2005</study_first_submitted>
  <study_first_submitted_qc>August 31, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2005</study_first_posted>
  <last_update_submitted>September 25, 2014</last_update_submitted>
  <last_update_submitted_qc>September 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
    <mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

